Conference Details


Organizing Committee


Bayhelix China Pharmaceutical Awards

Monday, October 17, 2016

6:00 PM to 8:00 PM

  • Welcome Reception
    Grand Hyatt Shanghai

    Hosted by Bristol-Myers Squibb, OrbiMed and BioCentury

Tuesday, October 18, 2016
  • Theme: Science, Innovation & Entrepreneurship in China

8:00 AM to 9:00 AM

  • Registration and Breakfast Networking

    Hosted by ICV Inc.

9:00 AM to 9:10 AM

  • Welcoming Remarks
    • David Flores, President & CEO, BioCentury Inc.
    • Kewen JIN, M.D., Chairman, BayHelix & Managing Partner, Serica Capital

9:10 AM to 10:00 AM

  • Setting the Stage: Lessons in Leadership

    The opening fireside chat challenges the Summit delegates to reflect on the leadership required to transform science, innovation and entrepreneurship in China.

    • Samantha Du, Ph.D., Founder, Chairman & CEO, Zai Lab Ltd.
    • Stanley Li, M.D., Founder, DXY
    • James Huang, Managing Partner, KPCB China (Session Chair)

10:00 AM to 11:15 AM

  • Science Showcase Plenary 1: China’s Research Pathfinders

    Leading Chinese biomedical researchers discuss China’s progress in immuno-oncology, cell therapy and precision medicine.

    • DONG Chen, Ph.D., Professor & Director, Institute for Immunology and Dean, School of Medicine, Tsinghua University (Featured Presenter)
    • XIAO Lei, Ph.D., Founder, President & CSO, Innovative Cellular Therapeutics Co. Ltd.
    • Simone Fishburn, Ph.D., Editor, BioCentury Innovations (Session Chair)

11:15 AM to 12:00 PM

  • Science Showcase Plenary 2: Innovation Requires Translation

    World class translational research is required to bring world class innovation to patients. Leading biomedical researchers and industry executives provide international perspectives on what’s needed to elevate translational performance in China.

    • DONG Chen, Ph.D., Professor & Director, Institute for Immunology and Dean, School of Medicine, Tsinghua University
    • Carl Firth, Ph.D., Founder & CEO, Aslan Pharmaceuticals Pte. Ltd.
    • Simone Fishburn, Ph.D., Editor, BioCentury Innovations
    • X. Shirley Liu, Ph.D., Professor, Harvard University, Dana-Farber Cancer Institute
    • Jimmy Wei, Ph.D., Managing Partner, I-Bridge Capital (Session Chair)

12:00 PM to 12:10 PM

  • Box Lunch Pickup and Networking

12:10 PM to 1:05 PM

  • Science Showcase Lunch Briefing: The State of China Tech Transfer

    A special report created for the China Healthcare Summit assesses what needs to be done to fully realize the social value of China’s investment in innovation, focusing on China’s technology transfer infrastructure and IP landscape, and using examples of important research emanating from China’s academic institutes.

    • Jun BAO, Ph.D., SVP & Chief Business Officer, Shenogen Pharma Group Ltd
    • Ruth Herzog, Ph.D., Head, Office of Technology Transfer, German Cancer Research Center, Heidelberg
    • Nisa Leung, Managing Partner, Healthcare, Qiming Venture Partners
    • Gordon Zong, CEO, Sinoipro IP Management & Technology Transfer Co. Ltd.
    • Jimmy Zhang, Ph.D., MBA, Managing Director, Cross-Border Investment, CL Investment Group (Session Chair)

1:05 PM to 1:45 PM

  • Science Showcase Perspectives: Global Developments in Immuno-Oncology

    Global R&D leaders from Bristol-Myers Squibb identify the latest global developments in immuno-oncology research.

    • Carl Decicco, Ph.D., SVP & Head of Discovery, Bristol-Myers Squibb Co.
    • Mathias Hukkelhoven, Ph.D., SVP, Global Regulatory, Safety and Biometrics, & Head of China R&D, Bristol-Myers Squibb Co.
    • Judith Li, Partner, Lilly Asia Ventures (Session Chair)

1:45 PM to 2:30 PM

  • Innovation Briefing 1: The Next Wave in China Medtech

    Top physicians, VCs and medtech executives discuss innovations that would most help patients and transform medical practice in China.

    • CHENG Jing, Ph.D., CEO, CapitalBio and Cheung Kong Professor, Tsinghua University
    • Lifei CHENG, Ph.D., VP, Strategy, Business Development & Ventures, Medtronic plc
    • HUANG Shiang, M.D., Founder & CEO, Wuhan Kindstar Diagnostics Co. Ltd.
    • WANG Jie, M.D., Ph.D., Co-founder & CEO, SyMap Medical (Suzhou) Ltd. and VP & Professor,
    • Jiangsu Academy of Clinical and Translational Research, Jiangsu Province Hospital
    • Victor Shi, Ph.D., Founding President, Asia Pacific, Qiagen (Session Chair)

2:30 PM to 3:15 PM

  • Innovation Briefing 2: How Public - Private Partnerships Can Help Address China's Public Health Challenges

    Spurred by China's Five-Year Plan, stakeholders in China are launching PPPs to create solutions to public health challenges, including antimicrobial resistance and infectious diseases like HIV, TB and HBV. This panel identifies the opportunities for collaboration and the challenges ahead.

    • Zhi HONG, Ph.D., SVP & Head of Infectious Diseases R&D, GlaxoSmithKline PLC
    • Alexander Ng, M.D., Deputy Director, China Program, Bill & Melinda Gates Foundation
    • Linqi ZHANG, Ph.D., Professor & Director, Comprehensive AIDS Research Center, Center for Global Health and Infectious Diseases, School of Medicine, Tsinghua University
    • John Cai, Ph.D., Director, Center for Healthcare Management and Policy, China Europe International Business School (Session Chair)

3:15 PM to 4:00 PM

  • Innovation Briefing 3: Precision Medicine Roundtable

    Given its large population and genome sequencing capacity, China's Precision Medicine Initiative could play an outsized role in identifying links between genetic mutations and disease. But how do we ensure these findings are translated into improved outcomes for Chinese patients?

    • Yanan CAO, M.D., Associate Research Fellow, Ruijin Hospital, Shanghai Jiao Tong University
    • Lei LIU, Ph.D., Professor, Fudan University
    • Yi WANG, M.D., Ph.D., VP, Children’s Hospital, Fudan University
    • Xiang S YE, Ph.D., Senior Director, Cancer Research China/Asia, Eli Lilly and Co.
    • Hongye SUN, Ph.D, Chief Technology Officer, WuXi NextCode (Session Chair)

4:00 PM to 5:00 PM

  • Innovation Showcase Plenary: Heads of Research Roundtable

    To meet China’s mandate for innovation, CSOs, CMOs and heads of R&D are building pipelines from both internal discovery and in-licensed assets. In this plenary, China heads of research discuss discovery and development models, and how to lead a scientific team in a rapidly changing industry.

    • Guoqing CAO, Ph.D., VP, Jiangsu Hengrui Medicine Co.
    • Hua MU, M.D., Ph.D., CSO & President, R&D, Simcere Pharmaceutical Group
    • Weiguo SU, Ph.D., EVP & CSO, Hutchison MediPharma Holdings Ltd.
    • Jiabing WANG, Ph.D., VP & Head of R&D Centers, Betta Pharmaceuticals Co. Ltd.
    • Zhengying ZHU, M.D., Ph.D., Deputy GM & CMO, Shandong Luoxin Pharmaceutical Group Stock Co.
    • Steve Yang, Ph.D., EVP & COO, WuXi AppTec (Session Chair)

5:00 PM to 5:35 PM

  • International Perspective: Voices from Abroad

    In a capstone rapporteur session, biotech leaders from the U.S. and Europe reflect on what they have heard in the day’s discussion of science, innovation and entrepreneurship in China.

    • Jie D’Elia, Ph.D., Executive Director, Business Development, Bristol-Myers Squibb Co.
    • Ruth Herzog, Ph.D., Head, Office of Technology Transfer, German Cancer Research Center, Heidelberg
    • Regina Hodits, Ph.D., General Partner, Wellington Partners
    • Martin Tolar, M.D., Ph.D., Founder, President & CEO, Alzheon Inc.
    • Peter Wirth, Chairman, FORMA Therapeutics Holdings LLC & Senior Advisor, Zai Lab Ltd.
    • Ian Wisenberg, CFO, BioDuro LLC
    • Karen Bernstein, Ph.D., Chairman, BioCentury Inc. (Session Chair)

5:35 PM to 5:40 PM

  • Closing Remarks

5:40 PM to 8:30 PM

  • Science, Innovation & Entrepreneurship Gala Reception and Networking Dinner

    Hosted by I-Bridge Capital, C-Bridge Capital Partners and BioCentury

Wednesday, October 19, 2016
  • Theme: Managing for the Future in China

8:00 AM to 8:50 AM

  • Registration and Breakfast Networking

    Hosted by Quintiles

9:00 AM to 10:00 AM

  • Walking the Bridge to Innovation: Key Findings from the 2016 China Healthcare Summit Report

    Insights Partner McKinsey & Co. analyzes the key findings from its 3rd exclusive report prepared for the China Healthcare Summit.

    • Franck Le Deu, Senior Partner & Head of Greater China Healthcare Practice, McKinsey & Co.

10:00 AM to 11:10 AM

  • View from the Top: Pharma & Medtech GM Perspective

    With major China regulatory reforms underway and the market continuing to experience headwinds, GMs from pharma and medtech MNCs discuss how they are managing for growth in China and building their organizations for success. 

    • Hong CHOW, General Manager, China, Shanghai Roche Pharmaceuticals Ltd.
    • James Deng, M.D., SVP & General Manager, Greater China, Becton Dickinson and Co.
    • Richard Ding, Corporate VP & Head, Asia-Pacific Region, bioMerieux S.A.
    • Karl Lintel, General Manager & President, China, Bristol-Myers Squibb Co.
    • Satoru Noguchi, Chairman, Takeda (China) Holdings Co. Ltd.
    • Christopher Round, President, MSD China
    • Gaobo ZHOU, Partner, McKinsey & Co. (Session Chair)

11:10 AM to 12:00 PM

  • Executive Briefing: CFDA Reforms Just the Beginning

    CFDA regulatory reforms are moving at warp speed. But can the benefits be realized without clinical trial reforms? This executive briefing identifies the key bottlenecks to conducting product development in China. 

    • Mike Dethick, Managing Director, RDPAC (R&D-based Pharmaceutical Association Committee)
    • Simon Sze, Manager, BioMedical Technology Cluster, Hong Kong Science & Technology Parks Corp.
    • George Yeh, President, Taiwan Liposome Co. Ltd.
    • Richard Yeh, Managing Director, Global Investment Research, Asia Pacific, Goldman Sachs (Asia) LLC
    • Dan Zhang, M.D., Chairman, Fountain Medical Development Ltd.
    • Ling ZHEN, SVP & General Manager, Greater China, Quintiles
    • Chen YANG, Head of China Life Sciences Practice, Sidley Austin LLP (Session Chair)

12:00 PM to 1:30 PM

  • 7th Annual BayHelix Awards and Lunch Keynote

    BayHelix once again celebrates outstanding individuals and companies for their achievement and contribution to China’s healthcare ecosystem in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year.

    • Jimmy Zhang, Ph.D., MBA, Managing Director, Cross-Border Investment, CL Investment Group (Masterof Ceremonies)
    • Yaoming Liang, Chairman & CEO, Guangzhou KingMed Center for Clinical Laboratory Co. Ltd. (Lunch Keynote)

1:30 PM to 2:15 PM

  • Plenary Roundtable: China and Biosimilars - Current Reality, Future Aspirations

    CFDA's biosimilars guidance has created broad outlines for policy. But how will the agency implement its guidance? And as more biosimilars aspirants crowd into China, what opportunities and challenges will they face? Key players in China biosimilars address these questions and more.

    • Stephen Doyle, VP & Head, Specialty Care, China, Boehringer Ingelheim GmbH
    • GAO Chengyu, Manager, Regulatory Strategy, Global Essential Health, Pfizer Inc.
    • Scott Liu, CEO, Shanghai Henlius Biotech Co. Ltd.
    • TAN Bo, CFO, 3SBio Inc.
    • Dan Zhang, M.D., Chairman, Fountain Medical Development Ltd. (Session Chair)

2:15 PM to 3:15 PM

  • Executive Case Study: Disrupting the Care Paradigm for Diabetes and Chronic Diseases in China

    Hospital reform in China demands innovation in patient care. At this executive briefing, stakeholders in diabetes and chronic diseases will demonstrate how new patient service approaches can connect mobile devices, hospitals and insurers to provide total medical services to patients.

    • Thomas Mickelson, Chief Marketing Officer, China, Eli Lilly and Co.
    • Stanley Li, M.D., Founder, DXY
    • Cathy Wang, Managing Director, China & Head of Operations, Asia Pacific, Now Health International (Shanghai) Ltd.
    • Wei ZHANG, Ph.D., M.D., Professor, Guanghua School of Management, Peking University (Session Chair)

3:15 PM to 4:00 PM

  • Executive Case Studies: Cross-Border Dealmaking

    Chinese companies and investors are rushing into cross-border deals to access innovation. But what makes a good deal? This panel uses case studies to address strategic models Chinese dealmakers need to consider. 

    • Dahai GUO, CEO, PuraCap Pharmaceutical LLC
    • Sammy Jiang, VP, International Business & Strategy, Luye Pharma Group Ltd.
    • Hui LI, Ph.D., VP, Business Development & General Manager, China, Sorrento Therapeutics Inc.
    • Frank Yu, Founder & CEO, Ally Bridge Group
    • Debra Yu, M.D., Managing Director & Head of Cross-Border Healthcare Investment Banking, China Renaissance Securities (Session Chair)

4:00 PM to 4:45 PM

  • Plenary Roundtable: Will Shanghai Become a Global Hub for Life Sciences Innovation?

    Shanghai and the Yangtze River Delta have grown into an innovation hub with the launch of many venture-backed start-ups, MNC R&D centers and public-private partnerships. But to become a complete global R&D hub, what other ingredients need to be provided by government, industry and other key stakeholders?

    • FU Daxu, Ph.D., Party Secretary, CPC & Deputy Director, Shanghai Center of Biomedicine Development
    • Edward Hu, CFO & Chief Investment Officer, WuXi Apptec
    • En LI, Ph.D., Head, China, Novartis Institutes for BioMedical Research
    • Da LIU, Business Development Director, China Resources (Holdings) Co. Ltd.
    • TAN Bo, CFO, 3SBio Inc.
    • XU Ming, Ph.D., VP, CCCMHPIE (China Chamber of Commerce for Import & Export of Medicines & Health Products)
    • Darren Ji, Ph.D., VP & Global Head of Partnering, Asia and Emerging Markets, Roche (Session Chair)

4:45 PM to 5:45 PM

  • Closing Plenary Roundtable : Is China Over-Heating in Healthcare?

    Chinese investors are bullish on biotech and healthcare, encouraged by exciting deal flow and regulatory reforms to support innovation. But can the enthusiasm get ahead of reality? In the closing plenary, leading investors and company executives reveal whether they detect danger signs, and debate how to manage investor expectations. 

    • Friedhelm Blobel, Ph.D., President & CEO, SciClone Pharmaceuticals Inc.
    • Brian Gu, Ph.D., Managing Director & Co-head Asia Pacific M&A, TMT, Healthcare & Sponsors, JP Morgan
    • Meng JIANG, Partner, C-Bridge Capital Partners LLC
    • Benjamin Li, Ph.D., CEO, Lee's Pharmaceutical Holdings Ltd.
    • Bin LI, Ph.D., CEO, Ally Bridge LB Healthcare Fund
    • Jonathan Wang, Ph.D., Co-founder & Senior Managing Director, OrbiMed Asia (Session Chair)

5:45 PM

  • Closing Remarks & Adjourn